Dermatologic treatment during pregnancy: how to weigh the risk:benefit ratio for mother and fetus

Authors: Maruani, Annabel; Perrinaud, Adeline; Machet, Laurent

Source: Expert Review of Dermatology, Volume 2, Number 2, April 2007 , pp. 233-241(9)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Drug administration can pose problems during pregnancy and requires careful evaluation of the risk:benefit ratio. This is well known with systemically administered drugs but more difficult to evaluate in the case of topical therapy, which reduces systemic diffusion and, hence, potential embryo- or feto-toxicity. In this review, we evaluate the risk:benefit ratio of both topical and systemic dermatologic drugs in order to provide pregnant women with clear information about the risks of any medication they are prescribed. In addition, fear of adverse events and of eventual prosecution must be balanced with the need to treat the expectant mother and the benefits.

Keywords: administration; adverse effects; dermatologic agents; drug therapy; guidelines; pregnancy; risk assessment; skin diseases; systemic; teratogen; topical

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17469872.2.2.233

Publication date: 2007-04-01

More about this publication?

Expert Review of Dermatology provides rapid publication of commentary and analysis on the latest research and clinical advances in all areas of dermatology, and of the challenges for this diverse specialty in a new medical era.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites